Wolverine Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Wolverine Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-64,800	Closed	-$5.68M	–	1619
2018 Q1	$5.68M	Buy	+64,800	New	+$5.92M	0.07%	253

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Wolverine Asset Management's XBI Position: Q1 2020 in Review

Wolverine Asset Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2020, closing a stake of 15,580 shares — an estimated $1.48M sold.

Wolverine Asset Management first reported a position in XBI in Q2 2017 and held it in 7 quarters. The position peaked at $1.64M in Q3 2019. 459 funds tracked by Wall St. Rank hold XBI as of Q1 2020.

Wolverine Asset Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2020 after selling out during the quarter.
Wolverine Asset Management sold 15,580 State Street SPDR S&P Biotech ETF shares in Q1 2020, an estimated $1.48M.
Wolverine Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and held it in 7 quarters.
Wolverine Asset Management's State Street SPDR S&P Biotech ETF position peaked at $1.64M in Q3 2019.
459 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2020.

Based on Wolverine Asset Management's 13F filing for Q1 2020, filed 13 May 2020.